Compare with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs ALEMBIC PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES ALEMBIC PHARMA ALKEM LABORATORIES/
ALEMBIC PHARMA
 
P/E (TTM) x 22.4 16.0 139.9% View Chart
P/BV x 5.4 6.4 84.9% View Chart
Dividend Yield % 0.9 0.6 149.9%  

Financials

 ALKEM LABORATORIES   ALEMBIC PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-20
ALEMBIC PHARMA
Mar-19
ALKEM LABORATORIES/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs2,720664 409.6%   
Low Rs1,660412 402.6%   
Sales per share (Unadj.) Rs697.9208.7 334.4%  
Earnings per share (Unadj.) Rs96.131.0 310.1%  
Cash flow per share (Unadj.) Rs117.337.1 316.0%  
Dividends per share (Unadj.) Rs25.005.50 454.5%  
Dividend yield (eoy) %1.11.0 111.7%  
Book value per share (Unadj.) Rs515.2144.2 357.3%  
Shares outstanding (eoy) m119.57188.52 63.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.12.6 121.7%   
Avg P/E ratio x22.817.4 131.2%  
P/CF ratio (eoy) x18.714.5 128.8%  
Price / Book Value ratio x4.33.7 113.9%  
Dividend payout %26.017.7 146.6%   
Avg Mkt Cap Rs m261,879101,461 258.1%   
No. of employees `00014.3NA-   
Total wages/salary Rs m15,0557,467 201.6%   
Avg. sales/employee Rs Th5,822.6NM-  
Avg. wages/employee Rs Th1,050.5NM-  
Avg. net profit/employee Rs Th802.0NM-  
INCOME DATA
Net Sales Rs m83,44439,347 212.1%  
Other income Rs m1,04294 1,111.1%   
Total revenues Rs m84,48639,441 214.2%   
Gross profit Rs m14,7348,736 168.7%  
Depreciation Rs m2,5281,152 219.4%   
Interest Rs m651184 353.4%   
Profit before tax Rs m12,5987,493 168.1%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-93 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,1051,568 70.5%   
Profit after tax Rs m11,4935,844 196.7%  
Gross profit margin %17.722.2 79.5%  
Effective tax rate %8.820.9 41.9%   
Net profit margin %13.814.9 92.7%  
BALANCE SHEET DATA
Current assets Rs m54,96019,577 280.7%   
Current liabilities Rs m32,43314,896 217.7%   
Net working cap to sales %27.011.9 226.9%  
Current ratio x1.71.3 128.9%  
Inventory Days Days8090 88.7%  
Debtors Days Days7245 159.1%  
Net fixed assets Rs m32,71027,097 120.7%   
Share capital Rs m239377 63.4%   
"Free" reserves Rs m61,36826,811 228.9%   
Net worth Rs m61,60727,188 226.6%   
Long term debt Rs m1,5924,993 31.9%   
Total assets Rs m99,43347,778 208.1%  
Interest coverage x20.441.7 48.8%   
Debt to equity ratio x00.2 14.1%  
Sales to assets ratio x0.80.8 101.9%   
Return on assets %12.212.6 96.8%  
Return on equity %18.721.5 86.8%  
Return on capital %21.023.6 88.8%  
Exports to sales %19.10-   
Imports to sales %3.00-   
Exports (fob) Rs m15,917NA-   
Imports (cif) Rs m2,483NA-   
Fx inflow Rs m16,06119,453 82.6%   
Fx outflow Rs m2,4836,065 40.9%   
Net fx Rs m13,57813,388 101.4%   
CASH FLOW
From Operations Rs m5,8518,120 72.1%  
From Investments Rs m-7,414-7,556 98.1%  
From Financial Activity Rs m792590 134.1%  
Net Cashflow Rs m-7311,153 -63.4%  

Share Holding

Indian Promoters % 66.9 74.1 90.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 2.9 1,141.4%  
FIIs % 0.0 9.1 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 13.9 -  
Shareholders   68,381 49,328 138.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   GSK PHARMA  ASTRAZENECA PHARMA  AJANTA PHARMA  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

A Time Correction in the Nifty(Momentum Moves)

The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 13.8% (Quarterly Result Update)

Jan 19, 2021 | Updated on Jan 19, 2021

For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)

Oct 23, 2020 | Updated on Oct 23, 2020

For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 33.3% (Quarterly Result Update)

Jan 23, 2020 | Updated on Jan 23, 2020

For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 25.2% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 25.2% YoY). Sales on the other hand came in at Rs 12 bn (up 10.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Mar 5, 2021 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS